Δευτέρα 27 Μαρτίου 2017

Positive CHMP opinion for Fluciclovine for PET imaging of recurrent prostate cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending that fluciclovine (18F) is granted marketing authorization in the European Union. The recommendation is for...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nmOAaO
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις